Adaptive Biotechnologies (ADPT) Total Liabilities (2018 - 2026)

Adaptive Biotechnologies has reported Total Liabilities for 9 years, with the latest figure at $281.7 million in Q1 2026.

• Quarterly Total Liabilities fell 12.14% year-over-year to $281.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $281.7 million (down 12.14% YoY) and the FY2025 annual result came in at $287.7 million, down 14.59% from the prior year.
• Total Liabilities fell to $281.7 million in Q1 2026 per ADPT's latest filing, from $287.7 million in the prior quarter.
• Over five years, Total Liabilities peaked at $396.4 million in Q3 2022 and troughed at $281.7 million in Q1 2026.
• A 5-year average of $334.2 million and a median of $336.9 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities declined 15.22% in 2022, then grew 27.84% in 2023.
• Over 5 years, Total Liabilities stood at $392.5 million in 2022, then decreased by 10.1% to $352.9 million in 2023, then dropped by 4.52% to $336.9 million in 2024, then retreated by 14.59% to $287.7 million in 2025, then fell by 2.1% to $281.7 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $281.7 million, $287.7 million, and $286.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.